Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure


Viral reservoirs that persist in HIV-1 infected individuals on antiretroviral therapy (ART) are the major obstacle to viral eradication. The identification and definition of viral reservoirs in patients on ART is needed in order to understand viral persistence and achieve the goal of viral eradication. We examined whether analysis of episomal HIV-1 genomes provided the means to characterize virus that persists during ART and whether it could reveal the virus that contributes to treatment failure in patients on ART. For six individuals in which virus replication was highly suppressed for at least 20 months, proviral and episomal genomes present just prior to rebound were phylogenetically compared to RNA genomes of rebounding virus after therapy interruption. Episomal envelope sequences, but not proviral envelope sequences, were highly similar to sequences in rebounding virus. Since episomes are products of recent infections, the phylogenetic relationships support the conclusion that viral rebound originated from a cryptic viral reservoir. To evaluate whether the reservoir revealed by episomal sequence analysis was of clinical relevance, we examined whether episomal sequences define a viral population that contributes to virologic failure in individuals receiving the CCR5 antagonist, Vicriviroc. Episomal envelope sequences at or near baseline predicted treatment failure due to the presence of X4 or D/M (dual/mixed) viral variants. In patients that did not harbor X4 or D/M viruses, the basis for Vicriviroc treatment failure was indeterminate. Although these samples were obtained from viremic patients, the assay would be applicable to a large percentage of aviremic patients, based on previous studies. Summarily, the results support the use of episomal HIV-1 as an additional or alternative approach to traditional assays to characterize virus that is maintained during long-term, suppressive ART.


Vyšlo v časopise: Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure. PLoS Pathog 7(2): e32767. doi:10.1371/journal.ppat.1001303
Kategorie: Research Article
prolekare.web.journal.doi_sk: 10.1371/journal.ppat.1001303

Souhrn

Viral reservoirs that persist in HIV-1 infected individuals on antiretroviral therapy (ART) are the major obstacle to viral eradication. The identification and definition of viral reservoirs in patients on ART is needed in order to understand viral persistence and achieve the goal of viral eradication. We examined whether analysis of episomal HIV-1 genomes provided the means to characterize virus that persists during ART and whether it could reveal the virus that contributes to treatment failure in patients on ART. For six individuals in which virus replication was highly suppressed for at least 20 months, proviral and episomal genomes present just prior to rebound were phylogenetically compared to RNA genomes of rebounding virus after therapy interruption. Episomal envelope sequences, but not proviral envelope sequences, were highly similar to sequences in rebounding virus. Since episomes are products of recent infections, the phylogenetic relationships support the conclusion that viral rebound originated from a cryptic viral reservoir. To evaluate whether the reservoir revealed by episomal sequence analysis was of clinical relevance, we examined whether episomal sequences define a viral population that contributes to virologic failure in individuals receiving the CCR5 antagonist, Vicriviroc. Episomal envelope sequences at or near baseline predicted treatment failure due to the presence of X4 or D/M (dual/mixed) viral variants. In patients that did not harbor X4 or D/M viruses, the basis for Vicriviroc treatment failure was indeterminate. Although these samples were obtained from viremic patients, the assay would be applicable to a large percentage of aviremic patients, based on previous studies. Summarily, the results support the use of episomal HIV-1 as an additional or alternative approach to traditional assays to characterize virus that is maintained during long-term, suppressive ART.


Zdroje

1. FinziD

HermankovaM

PiersonT

CarruthLM

BuckC

1997 Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278 1295 1300

2. WongJK

HezarehM

GunthardHF

HavlirDV

IgnacioCC

1997 Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278 1291 1227

3. ChunTW

StuyverL

MizellSB

EhlerLA

MicanJA

1997 Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94 13193 13197

4. SilicianoJD

KajdasJ

FinziD

QuinnTC

ChadwickK

2003 Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9 727 728

5. GunthardHF

FrostSD

Leigh-BrownAJ

IgnacioCC

KeeK

1999 Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 73 9404 9412

6. MartinezMA

CabanaM

IbanezA

ClotetB

ArnoA

1999 Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology 256 180 187

7. SharkeyM

TeoI

GreenoughT

SharovaN

LuzuriagaK

2000 Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy. Nat Med 6 76 81

8. ButlerSL

JohnsonEP

BushmanFD

2002 Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol 76 3739 3747

9. PiersonTC

KiefferTL

RuffCT

BuckC

GangeSJ

2002 Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 76 4138 4144

10. SharkeyM

TriquesK

KuritzkesDR

StevensonM

2005 In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol 79 5203 5210

11. ChomontN

El-FarM

AncutaP

TrautmannL

ProcopioFA

2009 HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15 893 900

12. ChavezHH

TranTA

DembeleB

NasreddineN

LambotteO

2007 Lack of evidence for prolonged double-long terminal repeat episomal HIV DNA stability in vivo. J Acquir Immune Defic Syndr 45 247 249

13. BuzónMJ

MassanellaM

LlibreJM

EsteveA

DahlV

2010 HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16 460 465

14. DelaugerreC

CharreauI

BraunJ

NereML

de CastroN

2010 Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. AIDS 24 2391 2395

15. ReigadasS

AndreolaML

WittkopL

CosnefroyO

AniesG

2010 Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells. J Antimicrob Chemother 65 434 437

16. McMahonD

JonesJ

WiegandA

GangeSJ

KearneyM

2010 Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 50 912 919

17. GandhiRT

ZhengL

BoschRJ

ChanES

MargolisDM

2010 The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 7 e1000321

18. ChunTW

DaveyRTJr

OstrowskiM

Shawn JustementJ

EngelD

2000 Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 6 757 761

19. ZhangL

ChungC

HuBS

HeT

GuoY

2000 Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest 106 839 845

20. ImamichiH

CrandallKA

NatarajanV

JiangMK

DewarRL

2001 Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis 183 36 50

21. Martinez-PicadoJ

FrostSD

IzquierdoN

Morales-LopetegiK

MarfilS

2002 Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals. J Virol 76 12344 12348

22. FinziD

BlanksonJ

SilicianoJD

MargolickJB

ChadwickK

1999 Latent infection CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5 512 517

23. SanchezG

XuX

ChermannJC

HirschI

1997 Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J Virol 71 2233 2240

24. YuJJ

WuTL

LiszewskiMK

DaiJ

SwiggardWJ

2008 A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients. Virology 379 78 86

25. TamuraK

DudleyJ

NeiM

KumarS

2007 MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24 1596 1599

26. SuZ

GulickRM

KrambrinkA

CoakleyE

HughesMD

2009 Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis 200 1724 1728

27. JoosB

FischerM

KusterH

PillaiSK

WongJK

2008 HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A 105 16725 16730

28. SahuGK

SarriaJC

CloydMW

2010 Recovery of Replication-Competent Residual HIV-1 from Plasma of a Patient Receiving Prolonged, Suppressive Highly Active Antiretroviral Therapy. J Virol 84 8348 8352

29. SahuGK

PaarD

FrostSDW

SmithMM

WeaverS

2009 Low-Level Plasma HIVs in Patients on Prolonged Suppressive Highly Active Antiretroviral Therapy Are Produced Mostly by Cells Other Than CD4 T-cells. J Med Virol 81 9 15

30. BrennanTP

WoodsJO

SedaghatAR

SilicianoJD

SilicianoRF

2009 Analysis of Human Immunodeficiency Virus Type 1 Viremia and Provirus in Resting CD4+ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy. J Virol 83 8470 8481

31. BaileyJR

SedaghatAR

KiefferT

BrennanT

LeePK

2006 Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells. J Virol 80 6441 6457

32. StrizkiJM

TremblayC

XuS

WojcikL

WagnerN

2005 Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 49 4911 4919

33. GulickRM

SuZ

FlexnerC

HughesMD

SkolnikPR

2007 Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 196 304 312

34. OgertRA

WojcikL

BuontempoC

BaL

BuontempoP

2008 Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 373 387 399

35. WhitcombJM

HuangW

FransenS

LimoliK

TomaJ

2007 Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 51 566 575

36. PauzaCD

TrivediP

McKechnieTS

RichmanDD

GrazianoFM

1994 2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo. Virology 205 470 478

Štítky
Hygiena a epidemiológia Infekčné lekárstvo Laboratórium

Článok vyšiel v časopise

PLOS Pathogens


2011 Číslo 2
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Eozinofilní granulomatóza s polyangiitidou
nový kurz

Betablokátory a Ca antagonisté z jiného úhlu
Autori: prof. MUDr. Michal Vrablík, Ph.D., MUDr. Petr Janský

Autori: doc. MUDr. Petr Čáp, Ph.D.

Farmakoterapie akutní a chronické bolesti

Získaná hemofilie - Povědomí o nemoci a její diagnostika

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Nemáte účet?  Registrujte sa

Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa